Pet Drug Reports

Species › Dog

Breed · Dog

English Cocker Spaniel: adverse event reports

FDA breed label "Spaniel - Cocker English" · single-breed animals only

1,084reports, 2008–20260.1% of dog reports
119reports, 12 months to March 202674 in the 12 months before
35%classed serious, as reportedall dogs: 38.3%
19%name fluralanerall dogs: 6.7%

FDA's database holds 1,084 reports where the animal's breed is given as "Spaniel - Cocker English", shown here as English Cocker Spaniel: 0.1% of reports about dogs. Reports on crossbred animals are left out of breed pages.

119 reports arrived in the 12 months to March 2026, up 61% from 74 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are fluralaner, milbemycin oxime + spinosad and ivermectin + pyrantel pamoate. Fluralaner is named in 19% of this breed's reports, a larger share than in reports about all dogs (6.7%).

The terms listed most often are vomiting (17.9%), lack of efficacy (ectoparasite) - flea (9.3%) and lack of efficacy (endoparasite) - hookworm (9.1%). Vomiting appears in 17.9% of reports, about the same share as in all dog reports (19.7%). 35% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drugReportsShare of English Cocker Spaniel reportsShare of all dog reports
Fluralaner20619%6.7%
Milbemycin Oxime + Spinosad18717.3%13.1%
Ivermectin + Pyrantel Pamoate15914.7%14.9%
Afoxolaner1049.6%5.7%
Spinosad666.1%5.8%
Pyrantel Pamoate + Sarolaner464.2%5.1%
Milbemycin Oxime + Praziquantel413.8%3.1%
Moxidectin302.8%5%
Oclacitinib282.6%2.9%
Afoxolaner + Moxidectin + Pyrantel Pamoate272.5%0.8%
Lufenuron + Milbemycin Oxime232.1%2.7%
Nitenpyram151.4%1.1%
Lotilaner141.3%1%
Carprofen131.2%4.8%
Cyclosporine131.2%1.5%
Lufenuron + Milbemycin Oxime + Praziquantel131.2%0.7%
Pimobendan131.2%0.6%
Cefpodoxime proxetil121.1%0.4%
Prednisone121.1%0.9%
Febantel + Praziquantel + Pyrantel Pamoate111%0.7%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of English Cocker Spaniel reports listing the termall dog reports

  1. Vomiting17.9%194
  2. Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]9.3%101
  3. Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]9.1%99
  4. Emesis[vomiting]8.3%90
  5. Diarrhoea[diarrhea]8.1%88
  6. Lethargy[unusually tired or inactive]6.9%75
  7. Lack of efficacy - NOS[the product did not have the expected effect]4.5%49
  8. Lack of efficacy (endoparasite) - heartworm[the product did not have the expected effect: heartworm]4.4%48
  9. Lack of efficacy (ectoparasite) - tick NOS[the product did not have the expected effect: ticks]3.4%37
  10. Seizure NOS[seizure, type not specified]3.4%37
  11. Emesis (multiple)[vomiting more than once]2.8%30
  12. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]2.7%29
  13. Lack of efficacy (endoparasite) - roundworm NOS[the product did not have the expected effect: roundworms]2.7%29
  14. Lack of efficacy (bacteria) - Borrelia[the product did not have the expected effect: Borrelia (Lyme disease bacteria)]2.3%25
  15. Behavioural disorder NOS[behaviour change, type not specified]2%22
  16. Other abnormal test result NOS[abnormal laboratory result, type not specified]2%22
  17. Anorexia[not eating]1.9%21
  18. Lack of efficacy (tick)[the product did not have the expected effect: ticks]1.9%21
  19. Death by euthanasia[the animal was euthanized]1.8%20
  20. Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]1.7%18
  21. Digestive tract disorder NOS[digestive problem, type not specified]1.6%17
  22. Shaking1.5%16

Age and weight

Age of the animal

Under 1 year9.9%107
1 to 3 years26%282
4 to 7 years26.5%287
8 to 11 years22.2%241
12 years and over12.6%137
Age not given2.8%30

Weight of the animal

Under 5 kg (11 lb)1.7%18
5 to 9.9 kg (11–22 lb)18.4%199
10 to 24.9 kg (22–55 lb)77%835
25 to 44.9 kg (55–99 lb)0.8%9
45 kg and over (99 lb+)0%0
Weight not given2.1%23

Coloured bar: English Cocker Spaniel reports. Grey bar: all dog reports.

Trend and outcomes

01121Apr 2021: 7May 2021: 12Jun 2021: 7Jul 2021: 8Aug 2021: 7Sep 2021: 3Oct 2021: 5Nov 2021: 12Dec 2021: 3Jan 2022: 42022Feb 2022: 1Mar 2022: 10Apr 2022: 3May 2022: 7Jun 2022: 4Jul 2022: 6Aug 2022: 6Sep 2022: 5Oct 2022: 5Nov 2022: 6Dec 2022: 2Jan 2023: 42023Feb 2023: 5Mar 2023: 5Apr 2023: 9May 2023: 10Jun 2023: 11Jul 2023: 6Aug 2023: 5Sep 2023: 4Oct 2023: 13Nov 2023: 7Dec 2023: 6Jan 2024: 22024Feb 2024: 5Mar 2024: 5Apr 2024: 7May 2024: 12Jun 2024: 8Jul 2024: 8Aug 2024: 8Sep 2024: 0Oct 2024: 10Nov 2024: 2Dec 2024: 8Jan 2025: 62025Feb 2025: 4Mar 2025: 1Apr 2025: 11May 2025: 6Jun 2025: 10Jul 2025: 16Aug 2025: 9Sep 2025: 8Oct 2025: 9Nov 2025: 11Dec 2025: 7Jan 2026: 52026Feb 2026: 6Mar 2026: 21

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal33.8%366
Recovered with Sequela3%32
Ongoing28%304
Died0.7%8
Euthanized1.9%21
Outcome Unknown32.7%354

Beside all dogs

MeasureEnglish Cocker SpanielAll dogs
Reports1,084985,675
Latest 12 months11953,292
Classed serious, of reports stating it35%38.3%
Death or euthanasia recorded, per 1,000 reports26.855

Questions about English Cocker Spaniel reports

How many FDA adverse event reports involve English Cocker Spaniels?

1,084 reports through March 2026, 0.1% of reports about dogs; 119 in the latest 12 months.

Which drugs are named most often in English Cocker Spaniel reports?

By active ingredient: fluralaner (206), milbemycin oxime + spinosad (187), ivermectin + pyrantel pamoate (159), afoxolaner (104) and spinosad (66). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (17.9%), lack of efficacy (ectoparasite) - flea (9.3%), lack of efficacy (endoparasite) - hookworm (9.1%), emesis (8.3%) and diarrhoea (8.1%).

Is the English Cocker Spaniel more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many English Cocker Spaniel animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Spaniel - Cocker English" becomes "English Cocker Spaniel"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.